APO RESEARCH · REPORT
Alzheimer's Disease Drug
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
Product & engineering
Understand the product.
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
Selected research
Industry Research
Alzheimer's Disease Drug Industry Research Report 2026
Market perspective
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
The major players in global Alzheimer’s Disease Drug market include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, etc. The top 3 players hold over 60% of global shares. Europe and North America are main markets, they occupy over 70% of the global market. Memantine and Donepezil are the main types, with a share about 70%. Early to Moderate Stages is the key application, which covers over 55% shares.
Report Scope
Read the full market overview
This report quantifies the global Alzheimer's Disease Drug market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Alzheimer's Disease Drug Market by Company
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck
Alzheimer's Disease Drug Segment by Type
Donepezil
Memantine
Rivastigmine
Others
Alzheimer's Disease Drug Segment by Application
Early to Moderate Stages
Moderate to Severe Stages
Alzheimer's Disease Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alzheimer's Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alzheimer's Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alzheimer's Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Alzheimer's Disease Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Alzheimer's Disease Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Alzheimer's Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Donepezil
- Memantine
- Rivastigmine
- Others
Applications
- Early to Moderate Stages
- Moderate to Severe Stages
Companies covered
- Allergan
- Eisai
- Novartis
- Daiichi Sankyo
- Merz Pharma
- Pfizer
- Johnson & Johnson
- Lundbeck
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Alzheimer's Disease Drug Market Size (2021-2032)
- 2.2.2 Global Alzheimer's Disease Drug Sales (2021-2032)
- 2.2.3 Global Alzheimer's Disease Drug Market Average Price (2021-2032)
- 2.3 Alzheimer's Disease Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Donepezil
- 2.3.3 Memantine
- 2.3.4 Rivastigmine
- 2.3.5 Others
- 2.4 Alzheimer's Disease Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Early to Moderate Stages
- 2.4.3 Moderate to Severe Stages
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Alzheimer's Disease Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Alzheimer's Disease Drug Sales (M Units) of Manufacturers (2021-2026)
- 3.3 Global Alzheimer's Disease Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Alzheimer's Disease Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Alzheimer's Disease Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Alzheimer's Disease Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Alzheimer's Disease Drug, Product Type & Application
- 3.8 Global Manufacturers of Alzheimer's Disease Drug, Established Date
- 3.9 Global Alzheimer's Disease Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Allergan
- 4.1.1 Allergan Company Information
- 4.1.2 Allergan Business Overview
- 4.1.3 Allergan Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Allergan Alzheimer's Disease Drug Product Portfolio
- 4.1.5 Allergan Recent Developments
- 4.2 Eisai
- 4.2.1 Eisai Company Information
- 4.2.2 Eisai Business Overview
- 4.2.3 Eisai Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eisai Alzheimer's Disease Drug Product Portfolio
- 4.2.5 Eisai Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Alzheimer's Disease Drug Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Daiichi Sankyo
- 4.4.1 Daiichi Sankyo Company Information
- 4.4.2 Daiichi Sankyo Business Overview
- 4.4.3 Daiichi Sankyo Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Daiichi Sankyo Alzheimer's Disease Drug Product Portfolio
- 4.4.5 Daiichi Sankyo Recent Developments
- 4.5 Merz Pharma
- 4.5.1 Merz Pharma Company Information
- 4.5.2 Merz Pharma Business Overview
- 4.5.3 Merz Pharma Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merz Pharma Alzheimer's Disease Drug Product Portfolio
- 4.5.5 Merz Pharma Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Alzheimer's Disease Drug Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Johnson & Johnson
- 4.7.1 Johnson & Johnson Company Information
- 4.7.2 Johnson & Johnson Business Overview
- 4.7.3 Johnson & Johnson Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Johnson & Johnson Alzheimer's Disease Drug Product Portfolio
- 4.7.5 Johnson & Johnson Recent Developments
- 4.8 Lundbeck
- 4.8.1 Lundbeck Company Information
- 4.8.2 Lundbeck Business Overview
- 4.8.3 Lundbeck Alzheimer's Disease Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lundbeck Alzheimer's Disease Drug Product Portfolio
- 4.8.5 Lundbeck Recent Developments
5 Global Alzheimer's Disease Drug Market Scenario by Region
- 5.1 Global Alzheimer's Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Alzheimer's Disease Drug Sales by Region: 2021-2032
- 5.2.1 Global Alzheimer's Disease Drug Sales by Region: 2021-2026
- 5.2.2 Global Alzheimer's Disease Drug Sales by Region: 2027-2032
- 5.3 Global Alzheimer's Disease Drug Revenue by Region: 2021-2032
- 5.3.1 Global Alzheimer's Disease Drug Revenue by Region: 2021-2026
- 5.3.2 Global Alzheimer's Disease Drug Revenue by Region: 2027-2032
- 5.4 North America Alzheimer's Disease Drug Market Facts & Figures by Country
- 5.4.1 North America Alzheimer's Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Alzheimer's Disease Drug Sales by Country (2021-2032)
- 5.4.3 North America Alzheimer's Disease Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Alzheimer's Disease Drug Market Facts & Figures by Country
- 5.5.1 Europe Alzheimer's Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Alzheimer's Disease Drug Sales by Country (2021-2032)
- 5.5.3 Europe Alzheimer's Disease Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Alzheimer's Disease Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Alzheimer's Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Alzheimer's Disease Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Alzheimer's Disease Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Alzheimer's Disease Drug Market Facts & Figures by Country
- 5.7.1 South America Alzheimer's Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Alzheimer's Disease Drug Sales by Country (2021-2032)
- 5.7.3 South America Alzheimer's Disease Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Alzheimer's Disease Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Alzheimer's Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Alzheimer's Disease Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Alzheimer's Disease Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Alzheimer's Disease Drug Sales by Type (2021-2032)
- 6.1.1 Global Alzheimer's Disease Drug Sales by Type (2021-2032) & (M Units)
- 6.1.2 Global Alzheimer's Disease Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Alzheimer's Disease Drug Revenue by Type (2021-2032)
- 6.2.1 Global Alzheimer's Disease Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Alzheimer's Disease Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Alzheimer's Disease Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Alzheimer's Disease Drug Sales by Application (2021-2032)
- 7.1.1 Global Alzheimer's Disease Drug Sales by Application (2021-2032) & (M Units)
- 7.1.2 Global Alzheimer's Disease Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Alzheimer's Disease Drug Revenue by Application (2021-2032)
- 7.2.1 Global Alzheimer's Disease Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Alzheimer's Disease Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Alzheimer's Disease Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Alzheimer's Disease Drug Value Chain Analysis
- 8.1.1 Alzheimer's Disease Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Alzheimer's Disease Drug Production Mode & Process
- 8.2 Alzheimer's Disease Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Alzheimer's Disease Drug Distributors
- 8.2.3 Alzheimer's Disease Drug Customers
9 Global Alzheimer's Disease Drug Analyzing Market Dynamics
- 9.1 Alzheimer's Disease Drug Industry Trends
- 9.2 Alzheimer's Disease Drug Industry Drivers
- 9.3 Alzheimer's Disease Drug Industry Opportunities and Challenges
- 9.4 Alzheimer's Disease Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst